Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Erasca, Inc.
  6. News
  7. Summary
    ERAS   US29479A1088

ERASCA, INC.

(ERAS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Erasca : Evercore ISI Starts Erasca at Outperform With $45 Price Target

08/10/2021 | 10:43am EST


ę MT Newswires 2021
All news about ERASCA, INC.
01/18Erasca Strengthens Leadership Team with Two Key Executive Appointments
GL
01/18Erasca Strengthens Leadership Team with Two Key Executive Appointments
GL
01/18Erasca, Inc. Announces Executive Changes
CI
01/12Certain Stock Options of Erasca, Inc. are subject to a Lock-Up Agreement Ending on 12-J..
CI
01/12Certain Common Stock of Erasca, Inc. are subject to a Lock-Up Agreement Ending on 12-JA..
CI
01/04Erasca to Present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
01/03Guggenheim Adjusts Price Target for Erasca to $20 From $25, Maintains Buy Rating
MT
2021ERASCA, INC.(NASDAQGS : ERAS) added to S&P Global BMI Index
CI
2021ERASCA, INC.(NASDAQGS : ERAS) added to NASDAQ Biotechnology Index
CI
2021Erasca Wins US FDA Clearance of IND Application for ERAS-801 in Glioblastoma Multiforme
MT
More news
Analyst Recommendations on ERASCA, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -133 M - -
Net cash 2021 103 M - -
P/E ratio 2021 -4,78x
Yield 2021 -
Capitalization 1 340 M 1 340 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 102
Free-Float -
Chart ERASCA, INC.
Duration : Period :
Erasca, Inc. Technical Analysis Chart | ERAS | US29479A1088 | MarketScreener
Technical analysis trends ERASCA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 11,05 $
Average target price 29,80 $
Spread / Average Target 170%
EPS Revisions
Managers and Directors
Jonathan E. Lim Chairman & Chief Executive Officer
David M. Chacko Chief Business Officer
Michael D. Varney Chairman-Research & Development
Wei Lin Chief Medical Officer
Nik Chetwyn Senior Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ERASCA, INC.-29.08%1 340
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508